Objective: Asymptomatic internal carotid artery occlusion (CO) presents a clinical dilemma, and presently, the natural history, stroke risk, and optimal management remain ill defined. This study compared outcomes, including neurovascular events (NVEs) and health care costs, between patients with CO and patients with asymptomatic carotid artery stenosis (CS).
Asymptomatic internal carotid artery occlusion (CO) is a condition with a variable natural history and unclear clinical significance. Neurovascular event rates among these patients have been reported as low as 0% at 6 years [1] [2] [3] [4] and as high as 26% at 2.6 years of follow-up. 5 More recently, Grubb et al 6 reported that the annual risk of any stroke in the setting of CO is somewhere between 5% and 7%, with a 2% to 6% risk of stroke per year occurring ipsilateral to the occluded carotid. Although CO is found in w15% of all patients presenting with cerebral infarction (stroke), 7 the true prevalence of CO remains unknown. 8 The quality and quantity of evidence to aid clinical management of CO is relatively low compared with that for asymptomatic internal carotid artery stenosis (CS). 5, 9 Most studies evaluating the risk of CO have focused on symptomatic patients because CO has been deemed to have a generally benign course. 10 The current treatment paradigm for patients with established CO prioritizes risk factor modification and medical management over any operative intervention. 8 For example, no stroke or survival benefit was found among patients with symptomatic CO who underwent intracranial bypass compared with medical therapy. 11 The purpose of this study was to compare outcomes, including neurovascular events (NVEs) and health care costs, between patients with CO and patients with CS. We hypothesized that NVEs and health care costs would both be higher in CO patients.
METHODS
Patient criteria. We identified patients with CO at an urban academic medical center between January 1, 2011, and December 31, 2013. Patients were identified using the General Surgical Outcomes Quality Improvement Database (SOCRATES) database, a prospectively collected and maintained general surgical outcomes quality improvement database designed to analyze processes and outcome measures. Inclusion criteria were based on duplex ultrasound imaging and lack of neurologic symptoms at time of carotid duplex. CS patients were included if they were noted to have a billing coding for asymptomatic moderately severe CS, which was defined as 50% to 79% (peak systolic velocity between 151 and 240 cm/s with marked spectral broadening), with varying degrees of simultaneous contralateral stenosis at time of duplex. 12, 13 These criteria were selected because asymptomatic patients with <80% CS are not routinely offered surgical intervention at our institution. CO patients were defined as those found to have unilateral occlusion with varying degrees of contralateral stenosis at time of duplex. None of the patients included in our analysis had bilateral CO. Exclusion criteria included any occurrence of neurovascular phenomena, defined as transient ischemic attack (TIA), amaurosis fugax, stroke, or stroke lesions on imaging related to the ipsilateral carotid artery at or #1 year before presentation. Patients without at least 6 months of follow-up were also excluded from the study. After exclusions, patients were grouped by CO or CS (Fig 1) . The Institutional Review Board reviewed and approved this human subjects study without the need for individual patient consent due to retrospective deidentified data collection and analysis.
Clinical variables. Baseline characteristics included age, gender, race, history of carotid endarterectomy (CEA), antiplatelet and statin medication documentation, and degree of contralateral stenosis. Follow-up data were gathered up to 1 year from presentation duplex assessment. Data included total cost accrued, number of hospital readmissions, general invasive procedures, vascular invasive procedures, and number of NVEs. All patients had comprehensive workup for events where appropriate, including hypercoagulability tests and echocardiography. A procedure defined as a vascular procedure in the database was a procedure performed by a vascular surgeon using a vascular billing code (ie, CEA) and did not include cardiac operations. There were no interventions on an occluded carotid artery directly. Vascular invasive procedures were not specific to carotid disease but rather included all procedures performed by a vascular surgeon during the 1-year follow-up period.
Patients were grouped according to the medication regimen that was documented for most of the follow-up period. The dollar figures quoted are revenue dollars collected against insurance claims.
Statistics. Statistical analyses were performed using R 3.2.5 software (R Foundation for Statistical Computing, Vienna, Austria). Baseline characteristics were summarized using descriptive statistics comparing the groups of patients with CO or CS using Student t-tests. A probability value P < .05 or 95% confidence interval that did not include 1.0 was considered statistically significant. To control for age and gender differences, CO patients were propensity matched with CS patients by the nearest-neighbor method. Multivariate analysis was performed by multiple linear regression modeling. Nonparametric Mann-Whitney analysis was used if groups did not satisfy the central limit theorem of at least 30 patients in each group in the analysis.
RESULTS
We identified 622 patients from our database who met inclusion criteria. Baseline characteristics of CO patients were compared with all CS patients (Table I) , and several significant differences were observed between the groups: In our unadjusted sample, CO patients were younger (72 years vs 75 years; P < .01) and more likely to be male (67% vs 53%; P ¼ .01). In an attempt to reduce these distribution differences, each CO patient was propensity matched with two CS patients by age and gender variables. Descriptive statistics were repeated, and the results are summarized in Table II . The differences between the groups resolved after propensity matching, with a trend toward higher use of statin therapy among patients with CO (92% vs 83%; P ¼ .05). Follow-up data were available for 99% of patients in the year after carotid duplex imaging. No significant difference was found in NVE based on degree of contralateral stenosis between groups or in contralateral CS severity between groups after propensity matching. We found 8% of our postmatched stenosis patients had severe contralateral stenosis, and among these, two patients experienced NVE during follow-up. One of these two received two operations on the moderately diseased carotid segment not the severely stenosed side. Among CS patients, 21 CEAs were performed during follow-up. Of the 32 patients with severe contralateral stenosis, only four underwent CEA during follow-up. Among CO patients, there were only two CEAs, again on the nonoccluded carotid artery.
After establishing groups of CO and CS patients with equivalent baseline characteristics, we turned our attention to patient outcomes. The mean NVE rate, cost, hospital admission rate, and number of procedures or operations for each group are reported in Table III . The rate of NVE was significantly higher among CO patients than among CS patients during the follow-up period (14% vs 7%; P < .01). Among those with NVEs, neither antiplatelet therapy (64% vs 77%; P ¼ .49) nor statin therapy (86% vs 77%; P ¼ .58) appeared to have a significant effect. Among the CO group, there were three (21%) ischemic NVEs ipsilateral to the occluded carotid artery against two (14%) contralateral events, with seven (50%) TIAs (Fig 2) . Cost ($14,361 vs $12,142; P ¼ .44) and hospital admission rate (63% vs 71%; P ¼ .18) were similar between groups. Not surprisingly, the rate of vascular procedures was higher in the CS group (55% vs 27%; P ¼ .04), likely as a result of increased use of CEA and the perception that these patients were at lower operative risk than CO patients. There were 21 carotid interventions in the CS group and two among CO patients during the follow-up period.
DISCUSSION
Data supporting what constitutes best medical therapy for CO are limited. In high-risk patients with a history of TIA or stroke of any cause, antiplatelet therapy reduced the risk of nonfatal stroke, myocardial infarction, or vascular death by 22% per 1000 patients treated.
14 Aspirin has been proven to reduce the risk of cardiovascular events in patients with TIAs or ischemic stroke of any cause 15 ; however, data supporting the use of a specific antiplatelet regimen in CO are limited. In fact, the most comprehensive evaluation of the topic recently concluded that more medical therapy data are needed. 16 In this study, we found patients with CO had a significantly higher rate of NVE despite similar overall cost and hospital readmission rates compared with CS patients. The annual rate of NVE ipsilateral to an occluded carotid was 3%, with an annual total TIA rate of 7%. Although seemingly high, our annual total TIA rate may be partly explained by the advanced age of our cohort or by the possible classification of indeterminate neurovascular phenomena as transient ischemic events. NVE rates were similar between the groups without any antiplatelet therapy, but this may be attributable to the low number of these patients or the greater number of carotid interventions for subocclusive disease among the CS group (n ¼ 21) compared with CO patients (n ¼ 2), underscoring the need for more aggressive medical intervention for CO patients. One explanation for the observed high rate of NVE in our study groups is the relatively advanced average age (72 years) of our CO cohort, with presumed commensurately elevated morbidity. In contrast, the average age of CO patients in the literature is 65 years 16 and 67 years in influential prospective trials. 9, 17 Of note, a subgroup analysis of the seven patients who progressed to ipsilateral CO in the Asymptomatic Carotid Stenosis Trial 1 (ACST-1) revealed ipsilateral NVE in 5 years, or w7% risk per year given the new occlusion. Furthermore, the criteria for enrollment for ACST-1 was a CS in the absence of symptoms for $6 months. In our current study, there was a mandatory 1-year asymptomatic period. Powers et al 10 cited four randomized trials that studied the issue of stroke risk in the CO population. Two studies reported the occurrence of one stroke in 72 patients monitored for 2 years, correlating with a very low risk of stroke. 10 Conversely the highest NVE rate reported in the literature noted seven events occurring in 49 patients with an average follow-up of almost 32 months. 18 The variability of stroke risk reported in CO literature suggests there is a need for clarity regarding the prognosis of CO. 19 Hackam 16 recently published a meta-analysis studying the current CO literature in an attempt to elucidate the prognosis of CO and the risk of stroke it carries. In their review of 13 studies involving 718 patients with median follow-up of 2.8 years, they found a 1.3% annual rate of ipsilateral stroke, with 2-and 5-year rates of stroke of 2.5% and 6.3%, respectively. The annual rate of ipsilateral TIA was 1.0%, with an annual total TIA rate of 3.0%.
Although their results support the notion that the risk of stroke in CO is indeed low, their reported 7.7% annual risk of death in CO patients suggests the cardiovascular risk is considerable. In addition, the search criteria for inclusion in the meta-analysis did not include the CO subgroups in asymptomatic CS trials (ie, 7% stroke risk among CO patients in the ACST trial), and thus, the observed NVE rate in this meta-analysis is lower than expected.
There have been no trials for antiplatelet therapy specific to CO patients, leaving the context in which our findings can be extrapolated open to question. Of the patients with CO in our sample, 15% were not prescribed any antiplatelet therapy at the time of their duplex ultrasound assessment. Many of these CO patients were undiagnosed previously, although it is possible that some previously diagnosed patients had not been prescribed antiplatelet therapy. The data may There were five ipsilateral ischemic strokes and two contralateral embolic strokes. B, Laterality of NVE among patients with asymptomatic carotid artery stenosis (CS). There were 6 ipsilateral strokes, 1 contralateral stroke, 1 vertebrobasilar stroke, 3 ipsilateral transient ischemic attacks (TIAs), 1 contralateral TIA, and 1 indeterminate TIA. also be due to the presence of anticoagulation or alternative antiplatelet therapy, although our study was not designed to capture these events. In addition, there is a surprising finding that a significant minority of our patients had not been prescribed statin therapy, with a nearly significant difference in statin use between the groups. We cannot conclude any effect resulting from statin use or nonuse from our data; however, these data should motivate all providers to vigilantly review prescribing habits for these at-risk patients. Hackam 16 concluded there were no trials of antiplatelet therapy in this population and recommended further investigation of statin and antiplatelet effect.
Our study has several limitations. Our nonrandomized retrospective analysis of prospectively collected data was not designed to adequately control for sample selection bias. To address this potential source of error between the groups, we adjusted for age and gender using propensity-score matching, although this cannot control for unmeasured baseline differences such as morbidity or adherence to medical therapy, including use of statin or anticoagulation therapy, or both.
Another limitation is the low number of patients analyzed. It is also possible that some patients in our sample did not return to our facility for management of an event or operation and thus would contribute to attrition bias. As with other studies of symptomatic carotid disease, an unknown percentage of patients with a history of TIA symptoms do not seek medical attention and are misclassified as asymptomatic. 16 It is true that we found no significant differences in the event rate in patients not receiving antiplatelets; however, the absence of significant difference is possibly a result of the low number of patients in the cohort, the nonparametric analysis, or other undocumented factors.
CONCLUSIONS
Our results suggest an increased risk of NVEs among patients with CO compared with CS. Our conclusions are tempered by the limitations of our small study; however, we believe this population is at greater than average risk of NVE and thus deserves further study. 
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